Athena Heart 310 -

Unlike daily pills or bi-monthly injections, CTX310 aims for a durable, permanent solution by editing DNA directly:

Targeted protein levels decreased by an average of 73%.

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets ATHENA HEART 310

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats.

Average drops of ~55% at the highest dose, with some patients seeing up to 84% reduction . Unlike daily pills or bi-monthly injections, CTX310 aims

Mean reductions of ~49%, with peak effects reaching 87% .

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1) By "turning off" this gene, the body can

Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: